<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">molbank</journal-id>
      <journal-title>Molbank</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Molbank</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Molbank</abbrev-journal-title>
      <issn pub-type="epub">1422-8599</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/M530</article-id>
      <article-id pub-id-type="publisher-id">molbank-2007-M530</article-id>
      <article-categories>
        <subj-group>
          <subject>Short Note</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Synthesis of Ethyl [4-(2-chlorobenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]acetate</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Benchat</surname>
            <given-names>Nour-Eddine</given-names>
          </name>
          <xref rid="c1-molbank-2007-M530" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Anaflous</surname>
            <given-names>Abderrahmane</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abouricha</surname>
            <given-names>Said</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ramdani</surname>
            <given-names>Mohammed</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>El-Bali</surname>
            <given-names>Brahim</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff id="af1-molbank-2007-M530">Department of Chemistry, University Mohamed I, Sciences Faculty, 60000 Oujda, Morocco</aff>
      <author-notes>
        <corresp id="c1-molbank-2007-M530"><label>*</label>Author to whom correspondence should be addressed. E-mail: <email>n_benchat@yahoo.fr</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>31</day>
        <month>05</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>05</month>
        <year>2007</year>
      </pub-date>
      <volume>2007</volume>
      <issue>2</issue>
      <elocation-id>M530</elocation-id>
      <history>
        <date date-type="received">
          <day>03</day>
          <month>01</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>06</month>
          <year>2006</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2007 by MDPI (http://www.mdpi.org/).</copyright-statement>
        <copyright-year>2007</copyright-year>
        <license>
          <p>Reproduction is permitted for noncommercial purposes.</p>
        </license>
      </permissions>
      <kwd-group>
        <kwd>pyridazin-3(2<italic>H</italic>)-one</kwd>
        <kwd>N-alkylation</kwd>
        <kwd>anticonvulsive agents</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
      <p>Pyridazines are of chemical and biological interest. They have been reported to be anticonvulsive agents [<xref ref-type="bibr" rid="B1-molbank-2007-M530">1</xref>], Furthermore, Gehrlein et al. have described the antihypertensive effects of novel hydroxyethylpyridazine compounds [<xref ref-type="bibr" rid="B2-molbank-2007-M530">2</xref>]. In continuation of this line of investigation, we have synthesized compound (I); it will be subjected to further pharmacological investigations, especially tests of its anticancer activity.</p>
	  <p><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2007-M530-i001.tif"/></p>
      <p>The product (II) was prepared from 5-(2-chlorobenzyl)-6-methylpyridazin-3(2H)-one (I) in situ by the solid-liquid PTC conditions without solvent [<xref ref-type="bibr" rid="B3-molbank-2007-M530">3</xref>]. To pyridazin (I) (1.4 g, 6 mmol) was added (2.75 g, 9 mmol) of potassium carbonate, (0.3 g, 1 mmol) of TBAB and (1 g, 6 mmol) of 2-ethyl bromoacetate. The mixture was placed in a pyrex tube which was then introduced into a Maxidigest MX 350 Prolabo microwave monomode reactor fitted with a rotational system. At the end of the irradiation time (10 min on 90 w as irradiation power), the mixture was cooled to ambient temperature. After elution with ethyl acetate (30 ml) and subsequent filtration on florisil, the organic product was purified by chromatography on silica gel using CH<sub>2</sub>Cl<sub>2</sub> as eluent, yield: 92 % of (II) solid. </p>
      <p>Melting point: 89-90&#xB0;C</p>
      <p>IR (KBr, cm<sup>&#x2212;1</sup>): 1747 (CO<sub>2</sub>Et), 1670 (C=O), 1605, 1470, 1210 (C = N)</p>
      <p><sup>1</sup>H-NMR (300.14 MHz, CDCl<sub>3</sub>) d (ppm): 1.28 (t, J = 7.5 Hz, 3H, CH<sub>3</sub>), 2.31(s, 3H, CH<sub>3</sub>), 3.38 (s, 2H, CH<sub>2</sub>), 4.25 (q, J = 5 Hz, 2H, CH<sub>2</sub>), 4.82 (s, 2H, CH<sub>2</sub>), 6.32 (s, 1H, H4), 7.20 (m, 4H, aromatic protons).</p>
      <p><sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>) d (ppm):14.11 (CH<sub>3</sub>), 19.03 (CH<sub>3</sub>) 35.77 (CH<sub>2</sub>), 52.68 (CH<sub>2</sub>), 61.66 (CH<sub>2</sub>), 127.71 (CH o), 127.42(CH aromatic), 129.02 (CH aromatic), 130.02 (CH aromatic), 131, 12 (CH aromatic) 134.43, 144.97, 145.17, 160.30 (C3), 167.72 (C=O).</p>
      <p>MS m/z (%) (M+1)<sup>+</sup> = 321.5, 279, 275,219.</p>
  </body>
  <back>
  <app-group>
    <app id="app1-molbank-2007-M530">
        <title>Supplementary materials</title>
        <supplementary-material id="molbank-2007-M530-s001" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2007-M530-s001-mod.mol">
   <label>Supplementary File 1</label>
</supplementary-material>
        <supplementary-material id="molbank-2007-M530-s002" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2007-M530-s001.mol">
   <label>Supplementary File 2</label>
</supplementary-material>
    </app>
</app-group>
    <ref-list>
      <title>References:</title>
      <ref id="B1-molbank-2007-M530">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Foussard-Blanc</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lacroix</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <source>Moniteur Int.</source>
          <year>1991</year>
          <volume>25</volume>
          <fpage>71</fpage>
          <lpage>84</lpage>
        </citation>
      </ref>
      <ref id="B2-molbank-2007-M530">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gehrlein</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Powers</surname>
              <given-names>L.J.</given-names>
            </name>
            <name>
              <surname>Eckert</surname>
              <given-names>D.J.</given-names>
            </name>
          </person-group>
          <source>J. Pharm. Sci.</source>
          <year>1981</year>
          <volume>70</volume>
          <fpage>419</fpage>
          <lpage>422</lpage>
        </citation>
      </ref>
      <ref id="B3-molbank-2007-M530">
        <label>3.</label>
        <note><p>(a) <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kappe</surname>
              <given-names>C.O.</given-names>
            </name>
            <name>
              <surname>Dallinger</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <source>Nature Reviews Drug Discovery</source>
          <year>2006</year>
          <volume>5</volume>
          <fpage>51</fpage>
        </citation>; (b) <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De la Hoz</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Diaz-Ortiz</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Moreno</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <source>Chem. Soc. Rev.</source>
          <year>2005</year>
          <volume>34</volume>
          <fpage>164</fpage>
        </citation></p></note>
      </ref>
    </ref-list>
  </back>
</article>
